Opening book details…
About this Medicine article
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase by Schiff, M. H.; von Kempis, J.; Goldblum, R.; Tesser, J. R.; Mueller, R. B. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Schiff, M. H.; von Kempis, J.; Goldblum, R.; Tesser, J. R.; Mueller, R. B.
- Publisher
- BMJ Publishing Group; BMJ (ISSN 0003-4967)
- Published
- 2014
- Language
- EN
- Field
- Medicine (Health Sciences)
More by Schiff, M. H.; von Kempis, J.; Goldblum, R.; Tesser, J. R.; Mueller, R. B.
Browse all works by Schiff, M. H.; von Kempis, J.; Goldblum, R.; Tesser, J. R.; Mueller, R. B.